People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. | — | Biotechnology | Series B | $15.9M | $259.4M | 2022 |
Michael Carson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Carson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ron Bentsur | 1 | 4 |
| Matthew Kaplan | 1 | 3 |
| Kenneth Hoberman | 1 | 3 |
| James Oliviero | 1 | 2 |
| Enrique Poradosu | 1 | 2 |
| Shay Shemesh | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.